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A B S T R A C T
Vagus nerve stimulation (VNS) is generally considered as a palliative treatment for patients with drug-
resistant partial onset epilepsy. Although seizure freedom can be occasionally achieved in patients with
VNS, anti-epileptic medications (AEDs) are commonly required to maintain seizure freedom. We report a
case that a patient became seizure free for 5 years with VNS monotherapy. To our knowledge, a similar
case has not been reported previously.
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VNS is an effective adjunctive therapy for patients with drug-
resistant partial onset epilepsy.1 It decreases seizure frequency by
approximately 50% in 30–40% of implanted patients.2 The efﬁcacy
of VNS has also been demonstrated in treating various types of
generalized epilepsies, including genetic generalized epilepsy
(GGE) and Lennox–Gastaut syndrome.3 Although VNS is primarily
a palliative treatment, seizure freedom has been reported in a
small percentage of patients. However, AEDs are commonly
required to maintain seizure freedom. Here we report that a
patient became seizure free with VNS monotherapy.
2. Case report
A 37-year-old, right-handed man started having seizures at age of
18. He reports monthly brief staring spells lasting for a few seconds,
and occasional generalized tonic clonic seizures at a frequency of 4–
5 times per year. His seizures are commonly precipitated by stress,
sleep deprivation and AED noncompliance. He was initially treated
with phenytoin (PTN) and carbamazepine (CBM) with minimal
beneﬁts. He was also treated with valproic acid (VPA), which
provided better seizure control, but it had to be discontinued due to
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daily and gabapentin (GBP) 1800 mg daily for the last several years.
His general physical and neurological examinations were
normal, as were his brain MRI and routine EEG. His family history
was noncontributory and past medical history was signiﬁcant for
HIV diagnosed at age of 28. His HIV infection has been well
controlled with medications and his viral counts have remained
undetectable. Although he has never had systemic infections
secondary to HIV, he has been debilitated by fatigue and drowsiness
due to the adverse effects of his medications, which has prevented
him from working. He was referred by his neurologist to our epilepsy
center for evaluation for possible VNS therapy.
Long-term video-EEG monitoring revealed 3–4 Hz generalized
spike-wave discharges (GSW) (Fig. 1). After complete withdrawal
of AEDs, the GSW became more frequent and were of longer
duration. One generalized tonic clonic seizure (GTC) was recorded
(Fig. 2). These EEG ﬁndings were consistent with IGE, likely
juvenile absence epilepsy. A vagus nerve stimulator was subse-
quently implanted in 2006. Final stimulation parameters were:
current output 1.75 mA, frequency 30 Hz, pulse width 500 ms, 30 s
signal on time, and 5 min signal off time; magnet-triggered current
2.0 mA and stimulation duration 60 s. The patient became seizure
free 3 months after the implantation and was gradually weaned off
GBP. After one year of seizure freedom, the patient voluntarily
discontinued his LTG. He has remained seizure free for almost 5
years, during which time he has been gainfully employed.
3. Discussion
In this particular patient, an incorrect use of narrow spectrum
AEDs and a history of AED noncompliance may have falsely createdEpilepsy Association.
Fig. 1. A burst of 3–4 Hz generalized spike wave discharges was recorded during long-term video-EEG monitoring.
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appropriate AED that was given an adequate clinical trial, albeit in
combination with GBP. VPA was discontinued due to adverse
effects. Perhaps monotherapy with other broad spectrum AEDs,
such as levetiracetam (LEV) or torpiramate (TPM), might have been
more effective, given that GGEs are often drug-responsive.4
Regardless, this patient was reluctant to try other AEDs prior to
the VNS implantation.Fig. 2. A generalized tonic clonic seizure was recorded after withdrawal of AEDs. The In general, patients with VNS rarely achieve seizure freedom.5
Only one of 198 (0.5%) patients became seizure free in an early
randomized active-control trial.1 In more recent uncontrolled case
studies, signiﬁcantly higher seizure freedom rates in patients with
VNS have been observed. Janszky et al. reported that 6 of 47 (13%)
patients became seizure free,6 while Ghaemi et al. reported that 10
of 144 (6.9%) patients became free of seizures.7 Treatment with
VNS earlier in the course of a seizure disorder has been associatedictal EEG onset was initiated with 3–4 Hz generalized spike and wave discharges.
S. Rose, J.X. Tao / Seizure 20 (2011) 735–737 737with a greater likelihood of improvement.8 AEDs were typically
required to maintain seizure freedom in these patients.
The patient in this study has been not only seizure free for 5 years,
but also AED-free after VNS implantation. Although spontaneous
seizure remission may occur in GGE, this is an unlikely scenario in
this patient, given his history of seizures precipitated by AED
noncompliance or withdrawal, as documented during long-term
monitoring. Instead, we believe that his remission was achieved by
VNS. We have heard of similar cases through personal communica-
tions, but they have not been formally reported in the literature.
Neurostimulation is a rapidly merging treatment for drug-resistant
epilepsy. Although palliative, rather than curative, the numbers of
patients achieving seizure freedom are likely to increase, particu-
larly with the addition of new techniques, including deep brain
stimulation (DBS) and responsive nerve stimulation (RNS). We
believe that it is clinically important to document such cases in the
hope of appreciating the clinical features of patients who have the
potential to become seizure free without AEDs.
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